Net monetary benefit from group B Streptococcus vaccination estimated to range from $1.1 to $17 billion
News and Features
This age group is now eligible to receive the booster dose at least 2 months after they complete primary vaccination with 3 doses of the monovalent vaccine.
M-M-R II, Varivax, and ProQuad are supplied in single-dose vials as lyophilized vaccine for SC or IM injection after reconstitution.
The FDA panel reviewed data from 5 clinical studies, including the phase 3 AReSVi 006 trial.
Pfizer has reported that its vaccine would reduce risk from RSV by as much as 86 percent
The BLA is supported by data from a phase 3 trial which included approximately 7400 pregnant individuals.
High vaccine efficacy seen against RSV A and B subtypes, across age groups among those aged 60 years and older, and for those with coexisting conditions
Vaccination results in lower RSV-mediated lower respiratory tract disease meeting one of three definitions
Several changes have been made to the child and adolescent immunization schedule for 2023.
Highly effective against delta, moderately effective against omicron infection and hospital admission in infants
Incidence of pertussis decreased among infants younger than 2 months after maternal Tdap vaccination implementation
Vaccine effectiveness against death was lower for patients aged 80 years and older
However, the Janssen COVID-19 vaccine was associated with increased risk at 21 and 42 days postvaccination
Vaccine effectiveness with at least one dose was 64 percent against serogroup B, 82 percent against non-serogroup B disease
Committee members also weighed a proposal to streamline the dosing schedule for COVID-19 vaccines by turning them into annual shots
Additional protection against symptomatic infection provided for people who had previously received monovalent vaccine doses
Authors found low adherence to CDC recommendations for boosters, with older adults more likely to receive at least four mRNA COVID-19 vaccine doses